CompletedPhase 1NCT01216046
Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects
Studying Cystic fibrosis-gastritis-megaloblastic anemia syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Principal Investigator
- Laurent Vernillet, PharmD, PhD, FCPVertex Pharmaceuticals Incorporated
- Intervention
- VX-809(drug)
- Enrollment
- 48 target
- Eligibility
- 18-55 years · All sexes
- Timeline
- 2010 – 2011
Study locations (1)
- PRA, Lenexa, Kansas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01216046 on ClinicalTrials.govOther trials for Cystic fibrosis-gastritis-megaloblastic anemia syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07071324CF Wellness ProgramJohns Hopkins University
- RECRUITINGNANCT07223255Gastrointestinal Response of Pediatric Cystic Fibrosis Patients on Mediterranean DietDartmouth-Hitchcock Medical Center
- RECRUITINGNANCT07031323OnTrackCF: Engagement, Feasibility, and Acceptability StudyBoston Children's Hospital
- ACTIVE NOT RECRUITINGNCT07147803Sleep Quality in Patients With Non-cystic Fibrosis BronchiectasisAssiut University
- RECRUITINGPHASE2NCT06998043Study With Phage for CF Subjects With Pseudomonas Lung InfectionBiomX Ltd
- RECRUITINGNCT06683092Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)Boston Children's Hospital
- RECRUITINGPHASE2NCT06559150A Phase II Study of Ensifentrine in Non-Cystic Fibrosis BronchiectasisVerona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
- RECRUITINGPHASE4NCT05704036Estrogen Supplementation and Bone Health in Women With CFJohns Hopkins University
See all trials for Cystic fibrosis-gastritis-megaloblastic anemia syndrome →